- PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2 expressing human pancreatic cancer cells
G.Eibl, D.Bruemmer, Y.Okada, J.P.Duffy, R.E.Law, H.A.Reber, O.J.Hines.
Biochem Biophys Res Commun 2003;306:887-897
- An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer
H.G.Hotz, H.A.Reber, B.Hotz, T.Yu, T.Foitzik, H.J.Buhr, G.Cortina, O.J.Hines.
Pancreas 2003;26:E89-98
- Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genestein, a naturally occurring isoflavonoid
P.Buechler, A.S.Gukovskaya, M.Mouria, M.C.Buechler, M.W.Buechler, H.Friess, S.J.Pandol, H.A.Reber, O.J.Hines.
Pancreas 2003;26:264-273
- Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer
J.P.Duffy, G.Eibl, H.A.Reber, O.J.Hines.
Mol Cancer 2003;2:12
- Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer
H.G.Hotz, O.J.Hines, B.Hotz, T.Foitzik, H.J.Buhr, H.A.Reber.
J Gastrointest Surg 2003;7:220-227
- Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer
P.Buechler, H.A.Reber, M.Buechler, S.Shrinkante, M.W.Buechler, H.Friess, G.L.Semenza, O.J.Hines.
Pancreas 2003;26:56-64
- The selective COX-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2
G.Eibl, H.A.Reber, M.N.Wente, O.J.Hines.
Pancreas 2003;26:33-41
- VEGF-RII influences the prognosis of pancreatic cancer
P.Buechler, H.A.Reber, M.W.Buechler, H.Friess, O.J.Hines.
Ann Surg 2002;236:738-749
- Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer
H.G.Hotz, P.S.Gill, R.Masood, B.Hotz, H.J.Buhr, T.Foitzik, O.J.Hines, H.A.Reber.
J Gastrointest Surg 2002;6:159-166
- Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis
M.Mouria, A.S.Gukovskaya, Y.Jung, P.Buechler, O.J.Hines, H.A.Reber, S.J.Pandol.
Int J Cancer 2002;98:761-769
- Solid and papillary epithelial neoplasms of the pancreas: aggressive resection for cure
D.Y.Yoon, O.J.Hines, A.J.Bilchik, K.Lewin, G.Cortina, H.A.Reber.
Am Surg 2001;67:1195-1199
- Identification of genes differentially induced by hypoxia in pancreatic cancer cells
D.Y.Yoon, P.Buechler, S.T.Saarikoski, O.J.Hines, H.A.Reber, O.Hankinson.
Biochem Biophys Res Commun 2001;288:882-886
- Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis
G.Eibl, M.N.Wente, H.A.Reber, O.J.Hines.
Biochem Biophys Res Commun 2001;287:522-529
- Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin)
P.Buechler, H.A.Reber, M.C.Buechler, M.A.Roth, M.W.Buechler, H.Friess, W.H.Isacoff, O.J.Hines.
J Gastrointest Surg 2001;5:139-146
- Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth
H.G.Hotz, H.A.Reber, B.Hotz, P.C.Sanghavi, T.Yu, T.Foitzik, H.J.Buhr, O.J.Hines.
J Gastrointest Surg 2001;5:131-138
- An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats
H.G.Hotz, H.A.Reber, B.Hotz, T.Foitzik, H.J.Buhr, G.Cortina, O.J.Hines.
Pancreas 2001;22:113-121
- G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation
N.M.Ryder, S.Guha, O.J.Hines, H.A.Reber, E.Rozengurt.
J Cell Physiol 2001;186:53-64
- Animal models of exocrine pancreatic cancer
H.G.Hotz, O.J.Hines, T.Foitzik, H.A.Reber.
Int J Colorect Dis 2000;15:136-143
- Evaluation of antimitotic activity of Rotula aquatica (lour): a traditional herb used in treatment of cancer.
S.Patil, S.Narayanan, G.Eibl, C.I.Jolly.
Indian J Exp Biol 2004;42:893-899
- Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells.
Y.Okada, G.Eibl, S.Guha, J.P.Duffy, H.A.Reber, O.J.Hines.
Clin Exp Metastasis 2004;21(4):285-292
- Growth stimulation of COX-2 negative pancreatic cancer by a selective COX-2 inhibitor.
G.Eibl, Y.Takata, L.G.Boros, J.Liu, Y.Okada, H.A.Reber, O.J.Hines.
Cancer Res 2005;65(3):982-990
- Broad spectrum G protein-coupled receptor antagonist [D-Arg1,D-Trp5,7,9,Leu11]SP: A dual inhibitor of growth and angiogenesis in pancreatic cancer.
S.Guha*, G.Eibl*, K.Kisfalvi, R.S.Fan, M.Burdick, H.A.Reber, O.J.Hines, R.Strieter, E.Rozengurt.
Cancer Res 2005;65(7):2738-2745
- Combination therapy for advanced pancreatic cancer using HerceptinÔ plus chemotherapy.
P.Buchler, H.A.Reber, G.Eibl, M.A.Roth, M.W.Buchler, H.Friess, W.H.Isacoff, O.J.Hines.
Int J Oncol 2005;27(4):1125-1130
- A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer.
G.Eibl, H.A.Reber.
Pancreas 2005;31(3):258-262
- Management of pancreatic fistulas after pancreaticoduodenectomy.
K.K.Kazanjian, O.J.Hines, G.Eibl, H.A.Reber.
Arch Surg 2005;140:849-855
- The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells.
M.N.Wente, G.Eibl, H.A.Reber, H.Friess, M.W.Buechler, O.J.Hines.
Oncol Rep 2005;14(6):1635-1638
- The G691S RET polymorphism increases GDNF-induced pancreatic cancer cell invasion by amplifying MAPK signaling.
H.Sawai, Y.Okada, K.Kazanjian, J.Kim, S.Hasan, O.J.Hines, H.A.Reber, D.S.B.Hoon, G.Eibl.
Cancer Res 2005;65(24):11536-11544
- PPAR-g ligands decrease pancreatic cancer cell invasion through modulation of the plasminogen activator system.
H.Sawai, J.Liu, H.A.Reber, O.J.Hines, G.Eibl.
Mol Cancer Res 2006;4(3):159-167
- Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective COX-2 inhibitor.
H.Funahashi, M.Satake, D.Dawson, N.-A.Huynh, H.A.Reber, O.J.Hines, G.Eibl.
Cancer Res 2007;67(15):7068-7071
- Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth.
H.Funahashi, M.Satake, S.Hasan, H.Sawai, R.A.Newman, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2008;36:353-362
- Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth.
H.Funahashi, M.Satake, S.Hasan, H.Sawai, R.A.Newman, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2008;36:353-362
- Distal Pancreatectomy: Incidence of Postoperative Diabetes.
J.King, K.Kazanjian, J.Matsumoto, H.A.Reber, M.W.Yeh, O.J.Hines, G.Eibl.
J Gastrointest Surg 2008;12(9):1548-1553
- Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. E.Angst, H.A.Reber, O.J.Hines, G.Eibl.
Surgery 2008;144:57-65
- Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
S.Hasan, M.Satake, D.D.Dawson, H.Funahashi, E.Angst, V.L.W.Go, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2008;37(2):121-127
- Induction of systemic disease-specific salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer.
K.Gao, H.Zhou, L.Zhang, J.W.Lee, Q.Zhou, S.Hu, J.Farrell, G.Eibl, D.T.Wong.
PLoS ONE 2009 Jun 11;4(6):e5875
- Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
K.Kisfalvi, G.Eibl, J.Sinnett-Smith, E.Rozengurt.
Cancer Res 2009;69(16):6539-6545
- Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the bcl-2 family.
I.Ohno, G.Eibl, I.Odinokova, M.Edderkaoui, R.D.Damoiseaux, M.Yazbec, R.Abrol, W.A.Goddard,III, O.Yokosuka, S.J.Pandol, A.S.Gukovskaya.
Am J Physiol Gastrointest Liver Physiol 2010;298:G63-G73
- Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors.
H.Pham, M.Chen, A.Li, J.King, E.Angst, D.W.Dawson, J.Park, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2010;39:332-339
- Epigenetic regulation affects N-myc downstream regulated gene-1 expression indirectly in pancreatic cancer cells.
E.Angst, D.W.Dawson, A.Nguyen, J.Park, V.L.W.Go, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2010 Feb 12 (Epub ahead of print)
- Bioluminescence Imaging of Angiogenesis in a Murine Orthotopic Pancreatic Cancer Model.
E.Angst, M.Chen, M.Mojadidi, O.J.Hines, H.A.Reber, G.Eibl.
Mol Imaging Biol 2010 April 8 (Epub ahead of print)
- Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts.
L.Zhang, E.Angst, J.Park, A.Moro, D.Dawson, H.Reber, G.Eibl, J.Hines, V.-L.Go, Q.-Y.Lu.
J Agric Food Chem 2010;58:7252-7257
- COX and PPAR: possible interactions in pancreatic cancer.
G.Eibl, H.A.Reber, O.J.Hines, V.L.W.Go.
Pancreas 2004;29(4):247-253
- Estrogen receptors in pancreatic tumors.
M.Satake, H.Sawai, V.L.W.Go, K.Satake, H.A.Reber, O.J.Hines, G.Eibl.
Pancreas 2006;33:119-127
- The role of PPAR-g and its interaction with COX-2 in pancreatic cancer. In special issue “PPARs: A Double-Edged Sword in Cancer Therapy”.
G.Eibl.
PPAR Res 2008;doi:10.1155/2008/326915
Please note: All information regarding overview, diagnosis, treatment options, and prognosis represent the general philosophy of Dr. Howard A. Reber and the other members of the Section of GI Surgery at UCLA. However, they are meant in no way to provide specific medical advice to any patient or patient's family member, friend, etc. Recommendations as to diagnosis, treatment options and prognosis should be sought from the patient's own physician.
|
|
